Accessibility Menu
Aardvark Therapeutics logo

Aardvark Therapeutics(NASDAQ) AARD

Market Cap$172.89MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2025)-45%
5 YearN/A
1 Year-34%
1 Month+50%
$7.52
-4.81%
-0.38Today
After hours$7.51-$0.01 (-0.13%)
Aardvark Therapeutics last closing stock price
MetricPriceDate
Last closeUSD 7.902026-08-07
Aardvark Therapeutics stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+19.7%USD 6.602026-07-31
1 month+49.62%USD 5.282026-07-08
3 month+45.22%USD 5.442026-05-08
Year to date-39.81%USD 13.132025-12-31
1 year-34%USD 11.972025-08-07
Since inception-44.79%USD 14.312025-02-13

Aardvark Therapeutics Financials at a Glance

Market Cap

$172.89MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.00

Net Income (TTM)

-$69.87M

EPS (TTM)

-$3.21

P/E Ratio

-2.46

Dividend

$0.00

Beta (Volatility)

1.95 (High)

Price

$7.52

Volume

91,505.135

Open

$7.76

Previous Close

$7.56

Daily Range

$7.26 - $7.76

52-Week Range

$3.35 - $17.94

Estimated Earnings Date

Aug 12, 2026

AARD News

Foolcom-Featured.png

Aardvark Therapeutics Reports Q2 Loss

Motley Fool Markets TeamAug 13, 2025

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Aardvark Therapeutics

Aardvark develops medicines for people with rare hunger and obesity disorders. Its main drug candidates aim to reduce excessive hunger in specific patient groups. The company’s work targets conditions with few existing treatment options.

What’s Cooking in the Lab?

  • ARD-101: Oral drug in late-stage trials for Prader-Willi Syndrome, a rare genetic disorder causing constant hunger (0% of revenue).
  • ARD-101 (other uses): Also tested for hypothalamic obesity, a condition linked to brain injury (0% of revenue).
  • ARD-201: Early-stage combination drug for obesity, mixing ARD-101 with a diabetes medicine (0% of revenue).
  • Non-TAS2R program: Low-dose naltrexone liquid for autism, still in development (0% of revenue).

Growth Spurts and Setbacks

  • IPO in February 2025 raised $87.5 million in net proceeds.
  • Launched Phase 3 HERO trial for ARD-101 in December 2024.
  • Expanded clinical trial sites to Australia in 2025, and to the UK, South Korea, and Canada in the first quarter of 2026.
  • Paused all ARD-101 and ARD-201 trials in February 2026 after cardiac safety signals.
  • As of February 28, 2026, Aardvark had 40 full-time employees.

Why Aardvark Stands Out

Aardvark focuses on rare diseases with few treatment options, using a unique approach that targets gut taste receptors. Its patent portfolio covers key drug candidates through 2042–2043. The company relies on third-party manufacturers and has no commercial products yet.

Five Things You Need to Know

  • No revenue reported for 2023, 2024, or 2025.
  • Net loss was $57.6 million in 2025, up from $20.6 million in 2024.
  • R&D expenses reached $48.9 million in 2025, up from $17.4 million in 2024.
  • Cash and investments totaled $110 million at December 31, 2025.
  • All clinical trials paused in February 2026 due to safety review.

Bottom Line

Aardvark is a young biotech focused on rare metabolic diseases, with no products on the market. Its future depends on resolving clinical trial safety issues and advancing its drug pipeline.

AI Generated • Apr 16, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

40

CEO

Tien Li Lee, MD

Website

www.aardvarktherapeutics.com

Headquarters

San Diego, CA 92122, US

AARD Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-61.71%

Return on Capital

-58.58%

Return on Assets

-70.87%

Earnings Yield

-40.65%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$172.89MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

21.88M

Volume

91.51K

Avg. Volume

268.48K

Financials (TTM)

Gross Profit

$0.00

Operating Income

-$74.72M

EBITDA

-$69.83M

Operating Cash Flow

-$61.65M

Capital Expenditure

-$95.00K

Free Cash Flow

-$61.75M

Cash & ST Invst.

$91.20M

Total Debt

$336.00K

Aardvark Therapeutics Performance Analysis

Aardvark Therapeutics annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 0N/A
20232023-12-31USD 0N/A
20242024-12-31USD 0N/A
20252025-12-31USD 0N/A
Aardvark Therapeutics sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30N/A
Q32025-09-30N/A
Q42025-12-31N/A
Q12026-03-31N/A
Aardvark Therapeutics annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -0.63N/A
20232023-12-31USD -0.34-46.9%
20242024-12-31USD -0.95181.5%
20252025-12-31USD -2.64178.2%
Aardvark Therapeutics sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30-53.5%
Q32025-09-30-13.6%
Q42025-12-31-8.0%
Q12026-03-31-22.2%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

$0.00

N/A

Gross Margin

0.00%

N/A

Market Cap

$172.89MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$4.32M

N/A

Employees

40

N/A

Net Income

-$21.59M

-131.9%

EBITDA

-$21.58M

-131.9%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$91.20M

-39.7%

Total Debt

$336.00K

-53.7%

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$0.00

-100.0%

Short Term Debt

$336.00K

-13.8%

Return on Assets

-70.87%

N/A

Return on Invested Capital

-85.90%

N/A

Free Cash Flow

-$18.87M

-65.7%

Operating Cash Flow

-$18.87M

-65.7%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
CRBUCaribou Biosciences, Inc.
$1.66+0.61%
TNYATenaya Therapeutics, Inc.
$0.74+1.46%
EPRXEupraxia Pharmaceuticals Inc.
$6.66-1.62%
NAUTNautilus Biotechnolgy, Inc.
$0.87-3.90%

Trending Stocks

Symbol / CompanyPricePrice Chg
SPCXSpace Exploration Technologies
$138.74+0.04%
ACHRArcher Aviation
$6.26+0.12%
NVDANvidia
$217.55-0.03%
INTCIntel
$97.52-0.04%

Questions About AARD

What is the current price of Aardvark Therapeutics?

Aardvark Therapeutics is trading at $7.56 per share.

What is the 52-week range for Aardvark Therapeutics?

Over the past 52 weeks, Aardvark Therapeutics has traded between $3.35 and $17.94.

How much debt does Aardvark Therapeutics have?

As of the most recent reporting period, Aardvark Therapeutics reported total debt of $336.00K.

How much cash does Aardvark Therapeutics have on hand?

Aardvark Therapeutics reported $62.44M in cash and cash equivalents in its most recent financial results.

What is Aardvark Therapeutics’s dividend yield?

Aardvark Therapeutics does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services